Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation

Completed · Early Phase 1

Conditions studied: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelogenous, Chronic, Multiple Myeloma

In brief

Contrast-enhanced abdominal CT will be performed 1-2 weeks after allogeneic stem cell transplant, and radiographic evidence of mucosal inflammation will be correlated with the subsequent development of acute graft versus host disease. The primary endpoint is the feasibility and safety of contrast-enhanced abdominal CT in the early post-transplant period, as defined by the risk of contrast-related nephropathy or allergic reaction.

Key facts

Study ID

NCT02117115

Run by

Washington University School of Medicine

People needed

21

Starts

2014-06-01

Expected to finish

2015-05-01

Last updated by the study team

2015-06-11

Who can join

Age: 20 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Biopsy-proven diagnosis of a hematologic malignancy
• Scheduled to undergo allogeneic SCT from a matched sibling donor or an unrelated donor who is 10/10 or 9/10 HLA match. Transplant eligibility is per standard and institutional criteria.
• Age 18-60 years
• Willing and able to provide informed consent

You may not qualify if…

• Documented or reported contrast allergy
• Estimated glomerular filtration rate (GFR) < 60
• Deemed too sick by clinician to leave the floor for imaging
• "Nothing-per-mouth" status for other clinical reasons
• Inclusion of Women and Minorities
• Both men and women and members of all races and ethnic groups are eligible for this trial.

Where it is running

• Washington University School of Medicine — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.